Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Darolutamide Liquid CAS 1297538-32-9 API Active Pharmaceutical Ingredient

Darolutamide Liquid CAS 1297538-32-9 API Active Pharmaceutical Ingredient

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 1297538-32-9

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Plastic bottles, Plastic buckets

Delivery Time: 7-15 days

Payment Terms: T/T, L/C, D/A, Western Union

Supply Ability: TON

Get Best Price
Highlight:

Darolutamide Liquid

,

Darolutamide CAS 1297538-32-9

,

CAS 1297538-32-9 API Active Pharmaceutical Ingredient

CAS NO::
1297538-32-9
Appearance::
Light Yellow Liquid
Molecular Formula::
C19H19ClN6O2
Molecular Weight::
398.846
EINECS NO::
829-313-8
MDL NO::
MFCD29472270
CAS NO::
1297538-32-9
Appearance::
Light Yellow Liquid
Molecular Formula::
C19H19ClN6O2
Molecular Weight::
398.846
EINECS NO::
829-313-8
MDL NO::
MFCD29472270
Darolutamide Liquid CAS 1297538-32-9 API Active Pharmaceutical Ingredient

Product Description:

Product Name: Darolutamide CAS NO:1297538-32-9

 

Synonyms:

ODM-201;

N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;

 

Chemical & Physical Properties:

Appearance: Light Yellow Liquid

Assay : ≥99.0%

Density:1.4 g/cm3

Boiling Point:719.5℃ at 760 mmHg

Flash Point:388.9℃

 

 

We can supply Darolutamide and intermediates:

Darolutamide Liquid CAS 1297538-32-9 API Active Pharmaceutical Ingredient 0

ODM-201, also known as Darolutamide, is a new-generation, potent and selective andr ogen receptor (AR) inhibitor which is potential useful for treatment of castration-resistant prostate cancer (CRPC). ODM-201 is a full and high-affinity AR antagonist that, similar to second-generation antiandrogens enzalutamide and ARN-509, inhibits testo sterone-induced nuclear translocation of AR. Importantly, ODM-201 also blocks the activity of the tested mutant ARs arising in response to antiandrogen therapies, including the F876L mutation that confers resistance to enzalutamide and ARN-509. In addition, ODM-201 reduces the growth of AR-overexpressing VCaP prostate cancer cells both in vitro and in a castration-resistant VCaP xenograft model. ODM-201 overcomes resistance to AR-targeted therapies by antagonizing both overexpressed and mutated ARs. ODM-201 is currently in a phase 3 trial in CRPC.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.